Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives $34.75 Average PT from Brokerages

Smith & Nephew SNATS, Inc. (NYSE:SNN) has received a consensus rating of “Hold” from the five brokerages that are covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $34.75.

Several equities analysts have recently issued reports on the company. Canaccord Genuity Group set a $32.00 price target on Smith & Nephew SNATS in a research note on Friday. Wall Street Zen raised Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research note on Sunday, March 29th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Monday, April 20th.

Institutional Investors Weigh In On Smith & Nephew SNATS

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SNN. Garner Asset Management Corp bought a new stake in Smith & Nephew SNATS in the fourth quarter valued at about $27,000. Arax Advisory Partners increased its holdings in Smith & Nephew SNATS by 142.6% in the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 569 shares during the last quarter. Advisors Asset Management Inc. bought a new stake in Smith & Nephew SNATS in the fourth quarter valued at about $36,000. Caitong International Asset Management Co. Ltd bought a new stake in Smith & Nephew SNATS in the third quarter valued at about $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Smith & Nephew SNATS in the fourth quarter valued at about $43,000. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Stock Performance

Shares of SNN opened at $32.11 on Friday. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS has a 12-month low of $26.58 and a 12-month high of $38.79. The stock’s fifty day simple moving average is $33.68 and its 200-day simple moving average is $33.85.

Smith & Nephew SNATS (NYSE:SNN) last issued its quarterly earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share (EPS) for the quarter. The firm had revenue of $1.60 billion for the quarter. Research analysts predict that Smith & Nephew SNATS will post 2.29 earnings per share for the current fiscal year.

Smith & Nephew SNATS Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Wednesday, May 27th. Investors of record on Friday, March 27th will be issued a $0.482 dividend. This represents a yield of 304.0%. The ex-dividend date is Friday, March 27th.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.